Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Bellicum Pharmaceuticals
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03733249CT.gov Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | — | Terminated | — | — | — |
NCT02231710CT.gov Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inborn Error Of Immunity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rivogenlecleucel (this asset) | Bellicum Pharmaceuticals | P1/2 | C · 39 |
| Treosulfan | medac GmbH | P2 | B |
| Busulfanum | medac GmbH | P2 | B |
| Fludarabine | Paul Szabolcs | P2 | B |
| Clofarabine | University of California, San Francisco | P2 | CCC |
| Melphalan | Paul Szabolcs | P2 | CCC |
| Cyclophosphamide | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | CCC |
| Alemtuzumab | Paul Szabolcs | P2 | CCC |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | CCC |
+7 more in the Inborn Error Of Immunity cohort
Other indications for Rivogenlecleucel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P2/3 | CCC · 48 |
| Myelodysplastic Syndrome | — | P2/3 | CC · 44 |
| Hemoglobinopathy | — | P1/2 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rivogenlecleucel in Inborn Error Of Immunity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rivogenlecleucel-inborn-error-of-immunity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →